JP2021521178A5 - - Google Patents

Info

Publication number
JP2021521178A5
JP2021521178A5 JP2020555501A JP2020555501A JP2021521178A5 JP 2021521178 A5 JP2021521178 A5 JP 2021521178A5 JP 2020555501 A JP2020555501 A JP 2020555501A JP 2020555501 A JP2020555501 A JP 2020555501A JP 2021521178 A5 JP2021521178 A5 JP 2021521178A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
independently
acceptable salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020555501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521178A (ja
JP7369139B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/026634 external-priority patent/WO2019199864A1/en
Publication of JP2021521178A publication Critical patent/JP2021521178A/ja
Publication of JP2021521178A5 publication Critical patent/JP2021521178A5/ja
Application granted granted Critical
Publication of JP7369139B2 publication Critical patent/JP7369139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020555501A 2018-04-10 2019-04-09 Pi3キナーゼおよびオートファジー経路の調節因子としての三置換アリールおよびヘテロアリール誘導体 Active JP7369139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862655741P 2018-04-10 2018-04-10
US62/655,741 2018-04-10
PCT/US2019/026634 WO2019199864A1 (en) 2018-04-10 2019-04-09 Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways

Publications (3)

Publication Number Publication Date
JP2021521178A JP2021521178A (ja) 2021-08-26
JP2021521178A5 true JP2021521178A5 (enExample) 2022-04-13
JP7369139B2 JP7369139B2 (ja) 2023-10-25

Family

ID=66248833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555501A Active JP7369139B2 (ja) 2018-04-10 2019-04-09 Pi3キナーゼおよびオートファジー経路の調節因子としての三置換アリールおよびヘテロアリール誘導体

Country Status (11)

Country Link
US (3) US11492348B2 (enExample)
EP (1) EP3774783B1 (enExample)
JP (1) JP7369139B2 (enExample)
KR (1) KR102803762B1 (enExample)
CN (1) CN112189012B (enExample)
AU (1) AU2019251360B2 (enExample)
EA (1) EA202092444A1 (enExample)
ES (1) ES3032793T3 (enExample)
MX (1) MX2020010576A (enExample)
SG (1) SG11202008832TA (enExample)
WO (1) WO2019199864A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112189012B (zh) * 2018-04-10 2024-02-13 神经孔疗法股份有限公司 作为pi3激酶和自噬途径的调节剂的三取代芳基和杂芳基衍生物
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
HRP20231310T1 (hr) * 2019-05-10 2024-02-02 Deciphera Pharmaceuticals, Llc Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
ES3072710T3 (en) 2019-06-17 2026-07-03 Deciphera Pharmaceuticals Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
CN113121499B (zh) * 2021-04-13 2022-05-31 海南锦瑞制药有限公司 奥美拉唑的合成方法及应用
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20081679A1 (es) 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
CA2675558A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
BRPI0915105A2 (pt) * 2008-06-13 2019-09-24 Novartis Ag composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
KR20120063515A (ko) 2009-09-09 2012-06-15 아빌라 테라퓨틱스, 인크. Pi3 키나제 억제제 및 이들의 용도
CN103501610A (zh) * 2011-03-09 2014-01-08 西建阿维拉米斯研究公司 Pi3激酶抑制剂和其用途
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
BR112016023811B8 (pt) * 2014-04-22 2023-01-10 Piqur Therapeutics Ag Método para fabricação para derivados de triazina, pirimidina e piridina, seus intermediários e seus métodos de fabricação
JP6397577B2 (ja) * 2014-12-17 2018-09-26 シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドShanghai Haiyan Pharmaceutical Technology Co., Ltd. 2−モルホリノ−4,6−二置換ピリミジン誘導体、その製法および医薬における使用
PT3416957T (pt) 2016-02-19 2020-09-25 Sprint Bioscience Ab Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
CN112189012B (zh) * 2018-04-10 2024-02-13 神经孔疗法股份有限公司 作为pi3激酶和自噬途径的调节剂的三取代芳基和杂芳基衍生物
US11236079B2 (en) 2018-04-10 2022-02-01 Neuropore Therapies, Inc. Morpholine derivates as inhibitors of Vps34

Similar Documents

Publication Publication Date Title
JP2013502431A5 (enExample)
JP2022544714A5 (enExample)
JP2018535963A5 (enExample)
JP2018536648A5 (enExample)
JP2021523200A5 (enExample)
JP2012532112A5 (enExample)
JP2013500314A5 (enExample)
JP2019524883A5 (enExample)
JP2013532652A5 (enExample)
JP2012526728A5 (enExample)
JP2011529918A5 (enExample)
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
WO2018075959A4 (en) Methods using hdac11 inhibitors
JP2010523522A5 (enExample)
JP2016515560A5 (enExample)
JP2019514956A5 (enExample)
JP2018531218A5 (enExample)
JP2013542267A5 (enExample)
JP2021535112A5 (enExample)
JP2016503797A5 (enExample)
JP2022511477A5 (enExample)
JP2010538094A5 (enExample)
JP2022500425A5 (enExample)
JP2013010792A5 (enExample)
JP7159440B2 (ja) ジカチオン化合物及びその製造方法と使用